Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 16c

February 27, 2019 7:39 AM EST

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.75), $0.16 better than the analyst estimate of ($0.91).

2018 was an important year for ITCI, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. The FDA accepted for review our NDA for lumateperone for the treatment of... More